Burkitt's lymphoma is a disease that can frequently be cured using intensive chemotherapy when found in younger patients. However, the high toxicity of this treatment programme makes it unsuitable for treating the disease when it occurs in elderly patients. Dr Antonio Pinto, Fondazione 'G. Pascale', Naples, Italy, explains how the treatment of older cancer patients will be addressed at the upcoming ecancer meeting on blood cancers in elderly patients to be held in Rome, 18-20th March 2011.

Dr Denburg speaks with ecancer at AORTIC 2017 about a trial to assess cost-effectiveness of treating Burkitt's lymphoma, a common childhood cancer, in Uganda.

He sets out the measures used to assess cost-effectiveness, noting the difference between that and affordability, and reports that interventions were found to be very cost effective.

selfless.medicose@gmail.com

Burkitt’s Lymphoma is a type of B cell lymphoma that is classically seen in african children and which without treatment is usually fatal.

Its pathogenesis is a wonderful example of cancer genetics.

It involves a gain of function mutation in the majorly important oncogene c-myc.

In this video we discuss this oncogene and how it becomes dysregulated in Burkitt’s lymphoma.

Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, comments on the results of the Phase II BURKIMAB14 trial (NCT05049473) evaluating the feasibility of dose reduction of chemotherapy after complete metabolic response (CMR) in young adults with Burkitt lymphoma and leukemia. The results demonstrated that this regimen decreased toxicity and did not have an impact on outcomes. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.